2-(2,6-dioxopiperidin-3-yl)-6,7-dihydro-5H-pyrrolo[3,4-f]isoindole-1,3-dione

Background Introduction

2-(2,6-dioxopiperidin-3-yl)-6,7-dihydro-5H-pyrrolo[3,4-f]isoindole-1,3-dione is a synthetic derivative closely related to thalidomide and its analogs, widely recognized as Cereblon (CRBN) E3 ligase ligands. These scaffolds form the essential E3 ligase-binding component in the construction of PROTACs (Proteolysis Targeting Chimeras), enabling researchers to direct the ubiquitin-proteasome system (UPS) towards selective protein degradation. With their robust binding affinity and favorable chemical properties, these derivatives serve as foundational elements for modern targeted protein degradation technologies.

Mechanism

This compound functions by specifically binding to the Cereblon (CRBN) substrate receptor within the CUL4A-DDB1-CRBN E3 ubiquitin ligase complex. Upon conjugation with a suitably designed linker and a target ligand, it acts as an efficient recruiter of the CRBN E3 ligase. The resulting PROTAC molecule juxtaposes CRBN and the protein of interest, promoting ubiquitination of the target protein, which leads to its recognition and degradation by the 26S proteasome. This mechanism allows for precise post-translational downregulation of previously 'undruggable' proteins.

Applications

2-(2,6-dioxopiperidin-3-yl)-6,7-dihydro-5H-pyrrolo[3,4-f]isoindole-1,3-dione is extensively utilized in the development of CRBN-based PROTACs and molecular glue degraders, making it an indispensable tool for early-stage drug discovery and chemical biology research. Key applications include:

• Synthesis of PROTACs targeting diverse disease-related proteins via the CRBN E3 ligase pathway
• Structure-activity relationship (SAR) studies to optimize PROTAC efficacy and selectivity
• Development of custom degrader molecules for validation and mechanism-of-action studies
• Pharmaceutical research projects and CRO contract synthesis of novel degrader compounds

This compound's versatility, stability, and binding efficiency make it a preferred choice for researchers seeking to advance the frontiers of targeted protein degradation therapy.

• High-purity compound verified by HPLC, NMR, and LC-MS
• Consistent batch-to-batch reproducibility with complete QC documentation
• Supplied with COA, MSDS, and analytical data for traceability
• Reliable global shipping with stability-guaranteed packaging
• Dedicated technical support and optional custom synthesis service
• Demonstrates strong binding affinity to CRBN, VHL, or other E3 ligases
• Enables stable E3 ligase recruitment for targeted protein degradation
• High-affinity CRBN ligand for efficient E3 ubiquitin ligase recruitment in PROTAC applications.
• Facilitates rapid development of targeted protein degradation molecules with proven efficacy.